StreetSmart Live! Presents Michael Ballanger on 10/26/2020. Learn More

The Latest Biotechnology / Pharmaceuticals Articles from Streetwise Reports


News Update

Biopharma White Paper Posits FDA Approval of Biogen's Alzheimer's Drug Likely Next Month

News Update
  ()
ProMIS Neurosciences cites "unequivocally positive data" and encouraging FDA actions with respect to the therapeutic. read more >
News Update

Biotech Secures Supplier of Psilocybin, Other Psychedelics

News Update
  ()
Revive Therapeutics will use these products in future studies and clinical trials. read more >

Aptinyx Shares Trade 17% Higher on Positive Top-Line Data in Phase 2 PTSD Trial

  ()
Aptinyx shares set a new 52-week high price after the company reported statistically significant, top-line data from its Phase 2 Study of NYX-783 in patients diagnosed with post-traumatic stress disorder. read more >

BioSpecifics Technologies Agrees to $658 Million Buyout Offer from Endo Pharmaceuticals

  ()
Biospecifics Technologies shares traded 45% higher after the company reported that it agreed to be acquired by Endo Pharmaceuticals for $88.50 per share in an all cash transaction. read more >

With Bases Loaded, NervGen Swings for the Fences in Traumatic Brain Injury

Contributed Opinion
  ()
Is there anything intracellular sigma peptide, the company's lead agent, can't do, asks Dr. KSS, MD, PhD, editor-in-chief of BioPub.co. read more >
News Update

Biopharma Announces Pulmonary Fibrosis Trial Now 25% Enrolled

News Update
  ()
Five sites in Australia and New Zealand are participating in this study of Algernon Pharmaceuticals' drug. read more >

Altimmune Publishes Compelling Preclinical Data for Intranasal COVID-19 Vaccine Candidate

  ()
Altimmune Inc. shares traded 12% higher after the company published preclinical studies conducted together with the University of Alabama at Birmingham for AdCOVID, its intranasal COVID-19 vaccine candidate. read more >

StreetSmart Live! Presents Algernon Pharmaceuticals

  ()
Algernon Pharmaceuticals CEO Christopher Moreau and guests fund manager Steve Palmer, Dr. Mark Swaim and Tony Pullen discuss the company's upcoming catalysts and events. read more >

Immunotherapy Firm Announces Positive Top-Line Trial Results for Severe and Critical COVID-19 Patients

Research Report
  ()
The study data and potential near-term catalysts for Enlivex Therapeutics are covered in an H.C. Wainwright & Co. report. read more >

Ocular Therapeutix Shares Rise 25% After Firm Reports 250% Sequential Increase in Q3 Revenue

  ()
Ocular Therapeutix shares reached a new 52-week high after the company reported that preliminary net product revenue increased to $5.8-5.9 million during Q3/20, representing a more than 250% increase over the previous quarter. read more >
News Update

Biopharma's Multinational COVID-19 Study Hits 75% Enrollment Mark

News Update
  ()
Algernon Pharmaceuticals expects completion of the clinical trial next month and data readout by year-end. read more >

MyoKardia Shares Don't Skip a Beat on $13.1 Billion Acquisition by Bristol Myers Squibb

  ()
Shares of MyoKardia traded 58% higher after the company reported that Bristol Myers Squibb has agreed to acquire the firm for $13.1 billion, or $225.00 per share in cash. read more >

AMAG Pharma Receives $647 Million Takeover Bid from Luxembourg Firm

  ()
Shares of AMAG Pharmaceuticals traded 44% higher after the company reported it has agreed to be acquired by Covis Group S.à r.l. for $13.75 per share in cash, or approximately $498 million on a fully diluted basis. read more >
News Update

Life Sciences Firm Finalizes First Sites for Phase 3 COVID-19 Trial

News Update
  ()
Enrollment for the study evaluating Revive Therapeutics' Bucillamine can now begin. read more >
News Update

Pharmaceutical Firm Completes Enrollment of 100 Patients in Phase 2b/3 COVID-19 Clinical Trial

News Update
  ()
Algernon Pharmaceuticals reported it has now enrolled 100 of 150 planned patients in its Phase 2b/3 human study of Ifenprodil for treatment of COVID-19. read more >

GENFIT and LabCorp Form Exclusive Partnership for Novel Liver Disease Diagnostic Test

  ()
GENFIT SA shares traded 30% higher after the company reported that it entered into an exclusive agreement with LabCorp to commercialize a novel diagnostic liver disease test. read more >
News Update

Pharmaceutical Firm Reaches 50% Enrollment Mark in Phase 2b/3 Ifenprodil COVID-19 Study

News Update
  ()
Algernon Pharmaceuticals reported it has enrolled the first 75 of 150 patients in a multinational Phase 2b/3 human study of Ifenprodil in treating SARS-CoV-2. read more >
News Update

Biotech to Develop Alzheimer's Disease Vaccine Using Proprietary Peptide Antigens

News Update
  ()
ProMIS Neurosciences has demonstrated positive outcomes in proof-of-concept studies. read more >

California-Based Biotech Receives COVID-19 Trial Clearance

Research Report
  ()
The timeline and next steps for Equillium's proposed Phase 3 clinical study are outlined in an H.C. Wainwright & Co. report. read more >

AIM ImmunoTech Achieves 200% Increase in Survival Results in Late-Stage Pancreatic Cancer Study

  ()
AIM ImmunoTech shares traded 20% higher after the firm reported it attained statistically significant, two-fold higher survival results in pancreatic cancer from research conducted at Erasmus University Medical Center in the Netherlands. read more >

FDA Grants Ampio Pharma IND and Approves Phase 1 Trial for Inhaled Ampion in COVID-19 Patients

  ()
Ampio Pharmaceuticals traded 15% higher reaching a new 52-week high after the company reported that the U.S. FDA granted an IND and approved the clinical trial protocol for inhaled Ampion for use in COVID-19 patients with respiratory distress. read more >
News Update

Biopharma Advances Development of Psilocybin-Based Therapeutics

News Update
  ()
Revive Therapeutics provides an update on its psychedelics therapeutics programs. read more >
News Update

Pharma Greenlighted to Continue Multinational COVID-19 Study

News Update
  ()
This confirms the safety of NP-120, the drug Algernon Pharmaceuticals is evaluating in this human trial. read more >

Sorrento Receives FDA Clearance to Proceed with Phase 1 COVID-19 Neutralizing Antibody Trial

  ()
Sorrento Therapeutics shares traded more than 10% higher after the company reported it received FDA approval to proceed with its Phase 1 clinical trial of STI-1499 (COVI-GUARD) Neutralizing Antibody in hospitalized COVID-19 patients. read more >
News Update

Expanded Access Protocol for Compassionate Use Approved for Patients with Severe COVID-19

News Update
  ()
Through this program of Revive Therapeutics, qualifying patients will receive Bucillamine, and the biopharma will obtain safety and efficacy data. read more >
Showing Results: 1 to 25 of 121 Next

Get Our Streetwise Reports Newsletter Free and be the first to know!

A valid email address is required to subscribe